Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVT-501 (tapinarof) in pediatric atopic dermatitis
NCT03415282Phase 1Unknown
- Sponsor
- Dermavant Sciences
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tapinarof in atopic dermatitis (AD), sponsored by Dermavant Sciences. Primary endpoints: Frequency and severity of adverse events (local and systemic) at 28 days, Laboratory values at 28 days and 3 more. Status: unknown.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03415282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415282.